Gohil Kunj, Carramusa Brielle
P T. 2014 Aug;39(8):576-7.
As new drugs emerge from the pipeline for the nearly 2 billion patients globally diagnosed with ulcerative colitis and Crohn's disease, sales of therapies for these conditions are expected to increase from $7.35 billion today to $11.05 billion in 2022.
随着针对全球近20亿被诊断患有溃疡性结肠炎和克罗恩病的患者的新药不断推出,这些病症的治疗药物销售额预计将从目前的73.5亿美元增长到2022年的110.5亿美元。